Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

Purpose: To describe real-world use of lanreotide combination therapy for acromegaly. Patients and methods: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated with lanreotide combination therapy between 2006 and 2011. 108 patients treated at 44 Spanish...

ver descrição completa

Detalhes bibliográficos
Autores: Puig-Domingo, M, Soto, A, Venegas, E, Vilchez, R, Blanco, C, Cordido, F, Lucas, T, Marazuela, M, Casany, R, Cuatrecasas, G, Fajardo, C, Galvez, MA, Maraver, S, Martin, T, Romero, E, Paja, M, Pico, A, Bernabeu, I, Resmini, E
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2016
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p7003
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7003
Access Level:acceso abierto
Palavra-chave:Acromegaly
Lanreotide
Cabergoline
Pegvisomant
IGF-I
Somatostatin analogues
id ES_e6debd704bf8da33bbbf87d3babe334f
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p7003
network_acronym_str ES
network_name_str España
repository_id_str
spelling Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB studyPuig-Domingo, MSoto, AVenegas, EVilchez, RBlanco, CCordido, FLucas, TMarazuela, MCasany, RCuatrecasas, GFajardo, CGalvez, MAMaraver, SMartin, TRomero, EPaja, MPico, ABernabeu, IResmini, EAcromegalyLanreotideCabergolinePegvisomantIGF-ISomatostatin analoguesPurpose: To describe real-world use of lanreotide combination therapy for acromegaly. Patients and methods: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated with lanreotide combination therapy between 2006 and 2011. 108 patients treated at 44 Spanish Endocrinology Departments were analyzed separately: 61 patients received lanreotide/cabergoline (cabergoline cohort) and 47 lanreotide/pegvisomant (pegvisomant cohort). Results: Patient median age was 50.8 years in the cabergoline cohort and 42.7 years in the pegvisomant cohort. Prior medical treatments were somatostatin analogue (SSA) monotherapy (40 [66%] patients) or dopamine agonists (7 [11%] patients) in the cabergoline cohort and SSA (29 [62%] patients) or pegvisomant monotherapy (16 [34%] patients) in the pegvisomant cohort. Across both cohorts 12 patients were previously untreated, and prior therapy was unknown/missing in 4 patients. Median duration of combined treatment was 1.6 years (0.1-6) and 2.1 years (0.4-6.3) in the cabergoline and pegvisomant cohorts, respectively. At baseline, median insulin growth factor (IGF)-I values were 149% upper limit of normal (ULN) (15-505%) in the cabergoline cohort and 156% ULN (15-534%) in the pegvisomant cohort, and decreased to 104% ULN (13-557%) p < 0.001 and 86% ULN (23-345%) p < 0.0001, respectively, at end of study (EOS). Normal age-adjusted values of IGF-I were obtained in 48% of lanreotide/cabergoline-treated patients and 70% of lanreotide/pegvisomant-treated patients at EOS. There were no significant changes in hepatic, cardiac or glycaemic parameters in either cohort. Conclusion: In clinical practice lanreotide treatment combinations are useful options for patients with acromegaly when monotherapy is insufficient; particularly, the combination of lanreotide and pegvisomant in patients not controlled with either SSA or pegvisomant alone has high efficacy and is well-tolerated. (C) 2016 SEEN. Published by Elsevier Espana, S.L.U. All rights reserved.ELSEVIER DOYMA SL2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7003Endocrinologia y NutricionISSN: 15750922ISSNe: 15792021reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Españolinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p70032026-06-14T12:41:47Z
dc.title.none.fl_str_mv Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
title Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
spellingShingle Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
Puig-Domingo, M
Acromegaly
Lanreotide
Cabergoline
Pegvisomant
IGF-I
Somatostatin analogues
title_short Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
title_full Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
title_fullStr Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
title_full_unstemmed Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
title_sort Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
dc.creator.none.fl_str_mv Puig-Domingo, M
Soto, A
Venegas, E
Vilchez, R
Blanco, C
Cordido, F
Lucas, T
Marazuela, M
Casany, R
Cuatrecasas, G
Fajardo, C
Galvez, MA
Maraver, S
Martin, T
Romero, E
Paja, M
Pico, A
Bernabeu, I
Resmini, E
author Puig-Domingo, M
author_facet Puig-Domingo, M
Soto, A
Venegas, E
Vilchez, R
Blanco, C
Cordido, F
Lucas, T
Marazuela, M
Casany, R
Cuatrecasas, G
Fajardo, C
Galvez, MA
Maraver, S
Martin, T
Romero, E
Paja, M
Pico, A
Bernabeu, I
Resmini, E
author_role author
author2 Soto, A
Venegas, E
Vilchez, R
Blanco, C
Cordido, F
Lucas, T
Marazuela, M
Casany, R
Cuatrecasas, G
Fajardo, C
Galvez, MA
Maraver, S
Martin, T
Romero, E
Paja, M
Pico, A
Bernabeu, I
Resmini, E
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Acromegaly
Lanreotide
Cabergoline
Pegvisomant
IGF-I
Somatostatin analogues
topic Acromegaly
Lanreotide
Cabergoline
Pegvisomant
IGF-I
Somatostatin analogues
description Purpose: To describe real-world use of lanreotide combination therapy for acromegaly. Patients and methods: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated with lanreotide combination therapy between 2006 and 2011. 108 patients treated at 44 Spanish Endocrinology Departments were analyzed separately: 61 patients received lanreotide/cabergoline (cabergoline cohort) and 47 lanreotide/pegvisomant (pegvisomant cohort). Results: Patient median age was 50.8 years in the cabergoline cohort and 42.7 years in the pegvisomant cohort. Prior medical treatments were somatostatin analogue (SSA) monotherapy (40 [66%] patients) or dopamine agonists (7 [11%] patients) in the cabergoline cohort and SSA (29 [62%] patients) or pegvisomant monotherapy (16 [34%] patients) in the pegvisomant cohort. Across both cohorts 12 patients were previously untreated, and prior therapy was unknown/missing in 4 patients. Median duration of combined treatment was 1.6 years (0.1-6) and 2.1 years (0.4-6.3) in the cabergoline and pegvisomant cohorts, respectively. At baseline, median insulin growth factor (IGF)-I values were 149% upper limit of normal (ULN) (15-505%) in the cabergoline cohort and 156% ULN (15-534%) in the pegvisomant cohort, and decreased to 104% ULN (13-557%) p < 0.001 and 86% ULN (23-345%) p < 0.0001, respectively, at end of study (EOS). Normal age-adjusted values of IGF-I were obtained in 48% of lanreotide/cabergoline-treated patients and 70% of lanreotide/pegvisomant-treated patients at EOS. There were no significant changes in hepatic, cardiac or glycaemic parameters in either cohort. Conclusion: In clinical practice lanreotide treatment combinations are useful options for patients with acromegaly when monotherapy is insufficient; particularly, the combination of lanreotide and pegvisomant in patients not controlled with either SSA or pegvisomant alone has high efficacy and is well-tolerated. (C) 2016 SEEN. Published by Elsevier Espana, S.L.U. All rights reserved.
publishDate 2016
dc.date.none.fl_str_mv 2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7003
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7003
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER DOYMA SL
publisher.none.fl_str_mv ELSEVIER DOYMA SL
dc.source.none.fl_str_mv Endocrinologia y Nutricion
ISSN: 15750922
ISSNe: 15792021
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422804725661696
score 15,811543

Registos relacionados